February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
409 citations
,
May 1991 in “Genes & Development” TGF-alpha affects skin thickness, hair growth, and may contribute to psoriasis and papilloma formation.
May 2022 in “Experimental dermatology” Trichothiodystrophy hair is structurally abnormal with protein and organization issues.
July 2025 in “Journal of Investigative Dermatology” TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.
28 citations
,
December 2005 in “Oncogene” 335 citations
,
March 2004 in “Development” Temporary activation of β-catenin can create new hair follicles, but ongoing activation is needed to keep hair follicle tumors.
March 2026 in “Science China Materials” SeV-Tp speeds up healing of drug-resistant infections by targeting wounds and killing bacteria with light activation.
10 citations
,
June 2011 in “Movement Disorders” THAP1 gene changes do not affect DYT1 dystonia; finasteride may help reduce tics and OCD in Tourette syndrome.
January 2013 in “edoc (University of Basel)” TRF1 is crucial for creating and maintaining stem cells and marks both pluripotent and adult stem cells.
October 2014 in “Cancer research” Blocking mTORC1 reduces skin tumor growth in mice.
36 citations
,
July 2017 in “Journal of controlled release” A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with fewer side effects.
19 citations
,
September 2011 in “Journal of Dermatological Science” TGF-β1 increases androgen receptor activity in hair loss, but Hic-5/ARA55 can counter this effect.
August 2012 in “Nature Cell Biology” A pathway helps maintain long telomeres in both stem and cancer cells.
November 2025 in “Journal of Investigative Dermatology” TEDAR is crucial for skin cell differentiation and barrier formation.
92 citations
,
June 2005 in “Journal of Investigative Dermatology” All-trans retinoic acid causes hair loss by increasing TGF-β2 in hair follicle cells.
April 2023 in “Journal of Investigative Dermatology” Acne patients have higher skin mTORC1 activity, which is reduced by isotretinoin treatment.
105 citations
,
May 2011 in “The journal of investigative dermatology/Journal of investigative dermatology” Activating TRPV3 stops human hair growth.
68 citations
,
August 2009 in “American Journal of Medical Genetics Part A” A new classification for trichothiodystrophy helps identify genetic causes and potential treatments.
79 citations
,
June 1993 in “Molecular and Cellular Biology” The K5 promoter controls gene expression in skin cells, with specific DNA segments crucial for targeting and regulation.
January 2024 in “Research Portal Denmark” H+-ATPase is crucial for plant growth and can be influenced by microbial compounds, affecting root hair development.
September 2019 in “The journal of investigative dermatology/Journal of investigative dermatology” Tet1/2/3 enzymes affect hair follicle cell development by influencing BMP signaling.
10 citations
,
August 2020 in “Acta histochemica” All-trans-retinoic acid stops mink hair growth by affecting cell growth and causing cell death.
April 2017 in “Journal of Investigative Dermatology” Triptolide effectively and safely reduces actinic keratosis lesions in mice.
18 citations
,
August 2015 in “Biochemical and Biophysical Research Communications” XEDAR triggers a specific signaling pathway in cells.
2 citations
,
June 2023 in “Journal of cell science” Mutations in iRhom2 affect hair and skin in mice and are linked to esophageal cancer, with ADAM17 playing a crucial role.
16 citations
,
October 2014 in “Journal of the American Academy of Dermatology” Oral retinoids may help some patients with hard-to-treat lichen planopilaris, but more research is needed.
2 citations
,
February 2023 in “International journal of molecular sciences” Tetrathiomolybdate reduces hair growth marker in skin cells by boosting harmful oxygen molecules, but effects can be reversed.
May 2026 in “Journal of Medicinal Chemistry” This study introduces dAR-6–1, a novel PROTAC designed for the transdermal treatment of androgenetic alopecia (AGA), featuring a pyridazinyl glutarimide moiety for enhanced CRBN binding. The compound demonstrates potent androgen receptor (AR) degradation with a DC50 of 0.90 nM and Dmax of 91% in LNCaP cells, and a DC50 of 0.23 nM and Dmax of 90% in hDPC cells, alongside exceptional solubility (>500 mg·mL–1). Both in vitro and in vivo studies, including an AGA mouse model, confirmed its superior skin permeability and hair regeneration efficacy compared to minoxidil. These findings highlight dAR-6–1 as a promising candidate for AGA treatment and offer a strategic framework for developing transdermal PROTACs.
4 citations
,
January 2023 in “Proteomes” Tumor proteins can both promote and suppress cancer, depending on the situation.
6 citations
,
June 2025 in “Nano Biomedicine and Engineering” Smart nano-PROTACs improve cancer treatment by targeting proteins more precisely and reducing side effects.